Sodium-dependent glucose transporter 2 inhibition and the atrial antiremodelling effects in HFrEF patients

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA‐MODA study

(2023) Domingo A. Pascual‐Figal et al.   EUROPEAN JOURNAL OF HEART FAILURE

Gliflozins in the Management of Cardiovascular Disease

(2022) Eugene Braunwald   NEW ENGLAND JOURNAL OF MEDICINE

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure

(2022) Riccardo M. Inciardi et al.   EUROPEAN JOURNAL OF HEART FAILURE

Atrial Failure as a Clinical Entity

(2020) Felipe Bisbal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Softening the Stiff Heart

(2020) Kim Connelly et al.   JACC-Cardiovascular Imaging

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

(2020) Carlos G. Santos-Gallego et al.   JACC-Cardiovascular Imaging

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors

(2019) Emily Brown et al.   DIABETES OBESITY & METABOLISM

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Atrial reverse remodelling is associated with outcome of cardiac resynchronization therapy

(2015) Mariëlle Kloosterman et al.   EUROPACE